跳至主要内容
临床试验/EUCTR2018-002226-22-AT
EUCTR2018-002226-22-AT进行中(未招募)1 期

The Impact of Target Temperature Management on Drug Metabolism - Cool PK

Medical University of Vienna0 个研究点目标入组 16 人开始时间: 2018年8月20日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
16

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Successful cardiopulmonary resuscitation (CPR) and target temperature management <34°C
  • >18 years of age
  • planned treatment with erythromycin, paracetamol, pantoprazole
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 26
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 26

排除标准

  • Increased inflammatory biomarkers at admission (C-reactive protein>5mg/dL), if available
  • Expected life expectancy <3 days
  • Patients with esophageal temperature <34.0°C at admission
  • Known liver dysfunction (i.e. liver cirrhosis, history of significant liver disorders)
  • Chronic kidney failure
  • Intake of known inducers or inhibitors of CYP2C19 or CYP3A4
  • Allergies of intolerances against any of the trial related substances
  • Prior erythromycin, pantoprazole or paracetamol treatment within 24 hours
  • Treatment with ciclosporin, tacrolimus, sirolimus, indinavir, ritonavir, saquinavir, or other drugs deemed relevant by the treating physician
  • Pregnancy or breastfeeding
  • Erythromycin: ongoing rhythm disturbances, such as ventricular tachycardias or ventricular fibrilliation

研究者

相似试验